GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
ElectroGas ‘proud to support Żibel’: ‘Protecting Malta’s seas requires practical action’
ElectroGas Malta partnered with Żibel, a Maltese environmental non-profit organisation dedicated to protecting the marine environment.
Christopher Curmi appointed Non-Executive Director of PG Group
Chistopher Curmi is a former Director and Partner of Deloitte Malta.
ATTO chief calls for ‘courage to speak up when policies do not make sense for Malta’
Cargo operators’ lobbyist Josef Bugeja made the comment in a meeting with PN Leader Alex Borg.
Maltese banking landscape ‘entering period of increased competition and change’ – BOV CEO
BOV is entering the next phase 'with a deep-rooted presence across Malta,' CEO says
